Research graph
References from OX40 ligand-engineered dendritic cell nanovesicles potentiate antitumor immunity through dual-mode T cell activation. Local targets link to admitted publications; unresolved targets remain external evidence.
CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review
10.1002/jcp.27782 · 2019 · External reference
Architects of immunity: how dendritic cells shape CD8(+) T cell fate in cancer
10.1126/sciimmunol.adf4726 · 2025 · External reference
Enhancing in situ cancer vaccines using delivery technologies
10.1038/s41573-024-00974-9 · 2024 · External reference
Nanocarriers based on bacterial membrane materials for cancer vaccine delivery
10.1038/s41596-022-00713-7 · 2022 · External reference
Dendritic cells in cancer immunology and immunotherapy
10.1038/s41577-019-0210-z · 2020 · External reference
DC-based cancer vaccines
10.1172/jci31205 · 2007 · External reference
An essential role for Akt1 in dendritic cell function and tumor immunotherapy
10.1038/nbt1262 · 2006 · External reference
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
10.1038/s41565-022-01098-0 · 2022 · External reference
Cell membrane-derived vesicle: a novel vehicle for cancer immunotherapy
2022 · External reference
Cell membrane coating technology: a promising strategy for biomedical applications
2019 · External reference
Engineered dendritic cells-derived extracellular vesicles for cancer immunotherapy
10.1016/j.jconrel.2025.113620 · 2025 · External reference
Locoregional immune checkpoint blockade and remodeling of lymph nodes by engineered dendritic cell-derived exosomes for suppressing tumor progression and metastasis
10.4028/b-xdtcg5 · 2025 · External reference
CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy
2023 · External reference
Dendritic cell biology and its role in tumor immunotherapy
10.1186/s13045-020-00939-6 · 2020 · External reference
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
10.1186/s12943-024-02179-5 · 2024 · External reference
Signaling through OX40 enhances antitumor immunity
10.1053/j.seminoncol.2010.09.013 · 2010 · External reference
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
10.1182/blood-2017-07-741025 · 2018 · External reference
Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory, and tumor elimination
10.1158/2326-6066.cir-15-0228 · 2016 · External reference
OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment
10.7150/thno.83495 · 2023 · External reference
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
10.1186/s40425-018-0454-3 · 2018 · External reference
Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia
10.1016/j.biomaterials.2018.08.018 · 2018 · External reference
A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering
10.1038/s41565-023-01533-w · 2024 · External reference
Cell surface and membrane engineering: emerging technologies and applications
10.3390/jfb6020454 · 2015 · External reference
RBD-modified bacterial vesicles elicited potential protective immunity against SARS-CoV-2
10.1021/acs.nanolett.1c00680 · 2021 · External reference
Synthetic biology-based bacterial extracellular vesicles displaying BMP-2 and CXCR4 to ameliorate osteoporosis
10.1002/jev2.12429 · 2024 · External reference
Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella
10.1038/s41467-024-50950-5 · 2024 · External reference
Cytolysin A is an intracellularly induced and secreted cytotoxin of typhoidal Salmonella
10.1038/s41467-024-52745-0 · 2024 · External reference
The assembly dynamics of the cytolytic pore toxin ClyA
10.1038/ncomms7198 · 2015 · External reference
The structure of a cytolytic alpha-helical toxin pore reveals its assembly mechanism
10.1038/nature08026 · 2009 · External reference
Current advancements in cellular immunotherapy for autoimmune disease
10.1007/s00281-024-01034-5 · 2025 · External reference
A review on the stability challenges of advanced biologic therapeutics
10.3390/pharmaceutics17050550 · 2025 · External reference
OX40/OX40 ligand and its role in precision immune oncology
10.1007/s10555-024-10184-9 · 2024 · External reference
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
10.1084/jem.20221166 · 2023 · External reference
Gene-guided OX40L anchoring to tumor cells for synergetic tumor “self-killing” immunotherapy
2023 · External reference
Enhanced antitumor immunity through T cell activation with optimized tandem double-OX40L mRNAs
10.2147/ijn.s479434 · 2025 · External reference
Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy
10.1002/smll.202006484 · 2021 · External reference
Membrane-wrapped nanoparticles for photothermal cancer therapy
10.1186/s40580-022-00328-4 · 2022 · External reference
Cell membrane as a promising therapeutic target: from materials design to biomedical applications
2024 · External reference
Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application
10.1016/j.apsb.2019.01.011 · 2019 · External reference
Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis
10.1021/acsnano.6b06477 · 2017 · External reference
Inhalable neutrophil-mimicking nanoparticles for chronic obstructive pulmonary disease treatment
10.1016/j.jconrel.2025.113648 · 2025 · External reference
Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes
10.7150/thno.50928 · 2021 · External reference
Engineered macrophage membrane-camouflaged nanodecoys reshape the infectious microenvironment for efficient periodontitis treatment
10.1021/acsnano.4c14305 · 2025 · External reference
Cancer vaccines: the next immunotherapy frontier
2022 · External reference
Novel personalized cancer vaccine using tumor extracellular vesicles with attenuated tumorigenicity and enhanced immunogenicity
2024 · External reference
Rethinking antigen source: cancer vaccines based on whole tumor cell/tissue lysate or whole tumor cell
2023 · External reference
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo
10.1002/eji.200939448 · 2009 · External reference
CAR-T therapy in solid tumors
10.1016/j.ccell.2025.03.019 · 2025 · External reference
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
10.1038/s41467-021-21099-2 · 2021 · External reference
Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade
10.1038/s41590-019-0312-6 · 2019 · External reference
